An innovative approach to meeting patient needs
Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including neurological and neurodegenerative diseases, migraine and movement disorders, as well as a strong portfolio of products to address respiratory disease, including asthma, severe asthma, allergic rhinitis, cystic fibrosis and Chronic Obstructive Pulmonary Disease (COPD).
Across our specialty medicines portfolio, we focus on developing, personalising and improving treatment of disorders for patients of the central nervous system, respiratory, oncology, and select local/regional therapeutic areas.
We integrate our generics and specialty capabilities in our global research and development division to create new ways of addressing unmet patient needs by combining medicine development capabilities with devices, services and technologies.
Exploring the potential of biopharmaceuticals
We are investing in both original biologic medicines and in biosimilars to help patients around the world. Biopharmaceuticals are complex medicines made from living cells or organisms. They advance more treatment options for patients, some of whom suffer from untreated or undertreated conditions. They have the potential to deliver precise and personalised treatment.
Biopharmaceuticals: Advancing more treatment options
We are investing in both original biologic medicines and in biosimilars to help patients around the world, and right here in the UK